Caitong International Asset Management’s Intensity Therapeutics INTS Stock Holding History

Caitong International Asset Management’s Portfolio INTS Stock Details INTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25	Buy	+6	New	+$28	﹤0.01%	2479

Other funds holding INTS

KCIA

Kingsbury Capital Investment Advisors Wilmette, Illinois $118M AUM

KWM

KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return

Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

MFIM

Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Caitong International Asset Management's INTS Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Intensity Therapeutics (INTS) in Q2 2026: 6 shares worth $25. The stake represents ﹤0.01% of the portfolio and ranks #2479 among its holdings.

17 funds tracked by Wall St. Rank hold INTS as of Q2 2026.

Caitong International Asset Management held 6 shares of Intensity Therapeutics worth $25 as of Q2 2026.
Intensity Therapeutics was a new Caitong International Asset Management position in Q2 2026.
Intensity Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2479 holding.
17 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.